On Friday, Goldman Sachs (NYSE:GS) initiated coverage on Teladoc Health Inc (NYSE:TDOC), assigning a Buy rating to the telehealth company's stock, accompanied by a price target of $14.00.
The coverage launch is based on a positive outlook for the company's integrated care business, particularly its Chronic Care Segment, which is expected to drive membership and revenue growth.
The analysis by Goldman Sachs foresees a turnaround in Teladoc's BetterHelp strategy, predicting that membership and utilization rates will reach their lowest point by the end of 2025, followed by growth. This anticipated growth is supported by direct cash payments and an emerging insurance model.
Furthermore, the firm anticipates that Teladoc's adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) will stabilize in 2025, with an inflection point expected in 2026 or later.
The financial institution's report suggests that as investors become more confident in Teladoc's consistent execution and the predictability of its financial performance, the company may experience upward adjusted EBITDA revisions and some multiple expansion. These factors are believed to have the potential to significantly drive up the stock's value.
Goldman Sachs' coverage on Teladoc Health reflects a belief in the company's future performance, indicating a positive outlook for the telemedicine provider in the upcoming years. The $14.00 price target represents a significant milestone for Teladoc as it continues to navigate the evolving digital healthcare landscape.
In other recent news, Teladoc Health disclosed its third-quarter financial outcomes for 2024, revealing a 3% year-over-year decrease in consolidated revenue to $641 million. Despite this, the Integrated Care segment saw a slight rise in revenue, up 2.5% to $384 million.
However, the BetterHelp segment faced a 10% drop in revenue, landing at $257 million. Adjusted EBITDA for the quarter was reported at $83.3 million, down 6% from the previous year, with a 13% margin.
The company's net loss per share improved to $0.19 from a loss of $0.35 in the same quarter last year. Free cash flow rose 16% year-over-year to $79 million, with over $1.2 billion held in cash by the company.
In terms of recent developments, for the fourth quarter, Teladoc projects Integrated Care revenue to be flat to up 2.5%, and adjusted EBITDA margins are estimated between 12.25% and 13.75%. The company's 2025 targets include revenue growth consistent with Q4 2024 trends, with an emphasis on maintaining margins and managing costs.
InvestingPro Insights
To complement Goldman Sachs' optimistic outlook on Teladoc Health Inc (NYSE:TDOC), recent data from InvestingPro offers additional context for investors. Despite the company's challenges, InvestingPro Tips highlight that Teladoc's valuation implies a strong free cash flow yield, which could support the potential turnaround scenario outlined by Goldman Sachs. This is particularly relevant given the anticipated stabilization of adjusted EBITDA by 2025.
However, it's important to note that InvestingPro data shows Teladoc's revenue growth at a modest 0.39% over the last twelve months, with a quarterly revenue decline of 2.99% in Q3 2024. This aligns with Goldman Sachs' projection that membership and utilization rates may reach their lowest point by the end of 2025 before rebounding.
On a positive note, Teladoc has demonstrated a strong return of 26.91% over the last three months, potentially reflecting growing investor confidence in the company's strategic direction. This recent performance could be an early indicator of the market beginning to price in the turnaround that Goldman Sachs anticipates.
For investors seeking a more comprehensive analysis, InvestingPro offers 6 additional tips for Teladoc Health, providing a deeper dive into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.